Myasthenia gravis (MG)
4 is a human autoimmune disorder manifested by muscle weakness and fatigability, occurring with a prevalence of 10 -100 per 1 000 000 (1 ) . The antigenic target is the nicotinic acetylcholine receptor (nAChR) of skeletal muscles. Detection and quantification of anti-nAChR antibodies in the serum of patients is used for the diagnosis of the disease and monitoring its course. Assays are mostly based on the design introduced by Lindstrom et al. (2 ) and use the immunoprecipitation of solubilized nAChRs prelabeled with 125 I-␣-bungarotoxin ( 125 I-␣-BuTx). The procedure is widely used, specific, sensitive, and thoroughly validated. However, working with radioactivity is associated with problems, such as limited life span of the labeled reagent, potential health hazards, and complicated disposal of radioactive waste.
High-sensitivity detection of lanthanides (comparable to the sensitivity for detection of 125 I) is possible by the use of time-resolved fluorescence methods, and those labels are used for measurement of numerous compounds (3) (4) (5) (6) . However, lanthanides cannot be used for direct labeling, and the compound to be detected (e.g., a protein) must first be derivatized with a suitable chelate, which is then complexed with the lanthanide.
We describe the preparation of Eu 3ϩ -labeled ␣-cobratoxin (␣-CTx; long neurotoxin from Naja naja kaouthia, which is highly similar to ␣-BuTx), which can be measured similar to the so-called dissociation-enhanced lanthanide fluorescence immunoassay (DELFIA), and demonstrate its use in an immunoassay for antibodies to nAChR. The assay procedure is analogous to that in routine use (2 ) and shows identical clinical specificity and an only slightly higher limit of detection (LOD).
Materials and Methods material and reagents
Venoms of Bungarus multicinctus and N. naja kaouthia were obtained from Latoxan;
125 I-labeled ␣-BuTx (specific activity, 8.2 TBq/mmol or 74 TBq/mmol) was from Amersham Pharmacia Biotech; diethylenetriaminepentaacetic acid (DTPA) anhydride and Eu(NO 3 ) 3 were from Sigma-Aldrich; Sephadex G-25, CM-Sephadex C-50, and mono-Q 5 ϫ 5 columns were from Pharmacia Biotech; octylSi300 (5 m) HPLC support was from Serva; antihuman IgG (QSwAHuIgG) was from Sevapharma; DELFIA enhancement solution was from Wallac Oy; TE671 cell culture was from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH; and Torpedo marmorata electric organs were from the Station Biologique dЈArcachon. All other chemicals were of analytical grade and were purchased mostly from SigmaAldrich.
purification of toxins ␣-CTx was purified from the venom of N. naja kaouthia by the procedure of Karlsson et al. (7 ) . ␣-BuTx was purified from the venom of B. multicinctus by a procedure similar to that described by Lee et al. (8 ) . Both toxins showed a single peak when tested by various HPLC analyses and were estimated to be at least 96% pure.
CTx labeling and purification of derivatives To 2 mg (0.25 mol) of ␣-CTx in 0.6 mL of 150 mmol/L sodium carbonate (pH 9.3), we added 16 mg of DTPA anhydride dissolved in 0.3 mL of dimethyl sulfoxide (in 50-L portions, with stirring) and left the mixture to react overnight at room temperature. The reaction mixture was then passed through a Sephadex G-25 column (1 ϫ 15 cm) preequilibrated with 50 mmol/L ammonium acetate. The toxin fraction (5 mL) was applied to a CM-Sephadex C-50 column (bed volume, 3 mL; preequilibrated with 50 mmol/L ammonium acetate). The wash-through fraction (12 mL) contained the derivatized toxin. The underivatized (native) toxin was retained on the resin and was washed out by 6 mL of 50 mmol/L ammonium acetate-0.4 mol/L NaCl. The derivatized fraction was concentrated by lyophilization, treated with 1 mmol/L Eu(NO 3 ) 3 , and further purified by reversed-phase and ion-exchange chromatography.
The Eu 3ϩ -treated fraction was loaded onto a 8 ϫ 80 mm column packed with octylSi300 (Serva) and eluted at 1 mL/min with the following gradient: 10% B for 5 min; 10 -70% B over 120 min; 70% B for 15 min; 70 -10% B over 10 min. The gradient system was as follows: solvent A, 1 g/L trifluoroacetic acid in water; solvent B, 1 g/L trifluoroacetic acid in 700 mL/L acetonitrile. The absorbance at 280 nm was monitored, and 4-mL fractions were collected.
Fractions from reversed-phase chromatography were further purified on a mono-Q column (5 ϫ 50 mm; Pharmacia) eluted at 0.5 mL/min with the following gradient profile: 0% B for 10 min; 0 -40% B over 90 min; 40 -100% B over 20 min. The gradient system was as follows: solvent A, 20 mmol/L ammonium acetate in 100 mL/L methanol; solvent B, 500 mmol/L ammonium acetate in 100 mL/L methanol. The absorbance at 280 nm was monitored, and 2-mL fractions were collected and concentrated by lyophilization.
determination of the affinity of derivatized ␣-CTx for nicotinic receptors
The relative affinity was determined by competition experiments in which different amounts of the derivatized ␣-CTx inhibited the binding of 125 I-␣-BuTx to AChR prepared from the electric organ of T. marmorata, according to the method of Fels et al. (9 ) .
culture of te671 cells
The rhabdomyosarcoma cell line of human origin, TE671, was the source of the nAChR. The use of this cell line was introduced for measurements of antibodies in myasthenia (10 -12 ) . Cells were grown, essentially as described by Somnier (13 ) , in DMEM containing 2 mmol/L glutamine and 100 mL/L fetal bovine serum in glass bottles (ϳ180 cm 2 ) in a 5% CO 2 atmosphere at 37°C, with seeding of ϳ3 ϫ 10 6 cells/bottle. On the 4th day, when cells approached confluence, the fetal bovine serum concentration was reduced to 10 mL/L, and the medium was supplemented with 2.5 mol/L dexamethasone and 100 mol/L nicotine. Cells were harvested on the 7th day of culture, washed, and centrifuged, and the pellet was kept at Ϫ65°C until further processing.
preparation and labeling of human nicotinic receptors
Triton X-100 extracts containing the receptors were prepared from human muscles (mostly from amputated legs from patients with complicated diabetes) by the procedure described by Lindstrom et al. (14 ) or from TE671 cells as described by Voltz et al. (15 ) . nAChR complexed with Eu 3ϩ -labeled ␣-CTx was prepared so that ϳ0.5 nmol/L nAChR was saturated to 60 -75% with the labeled toxin. The concentration required was first established by binding studies using different concentrations of the Eu 3ϩ -labeled ␣-CTx.
isotopic assay of myasthenic antibodies We incubated 0.2 mL of nAChR-Eu 3ϩ -␣-CTx complex (nAChR concentration ϳ0.5 nmol/L) with 10 L of human serum for 2 h at room temperature and then overnight at 4°C. Human IgG was then precipitated with anti-human IgG (100 L of QSwAHuIgG) during a 5-h incubation at room temperature. The resulting precipitate was centrifuged (10 min at 10 000g and 4°C), washed four times with 1 mL of phosphate-buffered saline, centrifuged (10 min at 10 000g and 4°C), and dissolved in 0.1 mL of "enhancement solution" (100 mmol/L acetate-phthalate, pH 3.2, 15 mol/L 2-naphthoyltrifluoroacetone, 50 mol/L tri-n-octylphosphine oxide, 1 mL/L Triton X-100). After an overnight incubation at room temperature, the contents were transferred from the test tubes to a microtitration plate, and time-delayed fluorescence was measured with a Victor 1420 Multilabel Counter (Wallac Oy), using the factory-set mode for Eu 3ϩ . Results preparation of the eu 3ϩ -labeled ␣-CTx derivative Approximately 60% of ␣-CTx was derivatized by DTPA under the described conditions. The Eu 3ϩ -labeled toxin was analyzed by reversed-phase HPLC, and several positional isomers were detected (Fig. 1) . Fractions isolated by HPLC were assayed for their relative affinity for nAChR by measuring their ability to inhibit the binding of 125 I-␣-BuTx to nAChR from electric organ membrane fragments. Fig. 2 shows the inhibition of binding of 125 I-␣-BuTx to AChRs by native and Eu 3ϩ -labeled ␣-CTx.
The concentration of Eu 3ϩ -labeled ␣-CTx required for half-maximal saturation of nAChR was ϳ50 times higher than the respective concentration of the native ␣-CTx.
Derivatives eluted at 0 -60 mL showed no measurable affinity for nAChR and contained ϳ30% of the applied toxin. Fractions eluting at ϳ110, 150, and 190 mL showed binding to nAChR, but their contribution was minor both in protein content and total binding capacity. The peak eluting between 60 and 90 mL contained ϳ60% of the derivatized ␣-CTx and the bulk of the total binding capacity for nAChR. Analysis by ion-exchange HPLC on a mono-Q column showed that this fraction contained three positional isomers, all of which were actively bound to nAChR. Therefore, a pool of the fractions eluting between 60 and 90 mL was used in the present work. The toxin derivatized by DTPA was fractionated on a semipreparative (8 ϫ 80 mm) reversed-phase macroporous column (octylSi300) by a linear gradient of acetonitrile in 1 g/L trifluoroacetic acid at a flow rate of 1 mL/min. Absorbance at 280 nm was monitored, and 4-mL fractions were collected. Fractions eluted between 60 and 92 mL were used for antibody assays. Ⅺ, BuTx binding equivalents; --, absorbance at 280 nm; Ϫ Ϫ Ϫ, percentage of acetonitrile. Fraction isolated by CM-Sephadex chromatography (as described in Materials and Methods) was used. K i (calculated for native ␣-CTx as 7.9 ϫ 10 Ϫ10 mol/L) was increased to 3.8 ϫ 10
Ϫ8 mol/L after derivatization, a factor of ϳ50-fold. Hill slope of the sigmoidal curve for the derivatized toxin differs significantly from 1, indicating the presence of a heterogeneous population of binding sites. Hill slope for the curve for native ␣-CTx is 1.
binding of eu

3ϩ -labeled ␣-CTx to receptors
To measure the binding of Eu 3ϩ -labeled toxin to solubilized nAChRs from human muscle, we used immunoprecipitation with a highly positive MG serum. Binding of our Eu 3ϩ -labeled toxin preparation was specific and saturable (Fig. 3A) , with two different apparent affinities: 3.7 ϫ 10 Ϫ9 mol/L (ϳ40%) and 145 ϫ 10 Ϫ9 mol/L (ϳ60%). For comparison, similar results with 125 I-␣-BuTx are shown in Fig. 3B. titration of myasthenic sera in eu 3ϩ assay
To detect antibodies in myasthenic sera, we used 100 fmol of nAChR saturated to 60 -75% with Eu 3ϩ -␣-CTx. The Eu 3ϩ -␣-CTx-nAChR complexes were prepared "in bulk" and were stable for at least 1 year if stored in appropriate aliquots (to avoid repeated thawing and freezing) at Ϫ80°C (data not shown). Receptors extracted from both sources (TE 671 cells or human muscles) showed similar suitability for the assay.
Examples of the titration of individual myasthenic sera are shown in Fig. 4 . Taking into account the differences in specific activity of the two toxins, the shapes of individual titration curves obtained were very similar. The specific activity of the Eu 3ϩ -labeled ␣-CTx preparation used in this study was 1500 fluorescence counts/fmol. Negative sera typically gave 11 300 Ϯ 1050 (mean Ϯ SD) fluorescence counts, and the same background values were obtained when specific binding of the label was blocked by an excess of cold ␣-BuTx (10 Ϫ7 mol/L). We used three 10-L serum aliquots for the initial estimation of the titer. If Ͼ20% of the available Eu 3ϩ -␣-CTx-nAChR complex precipitated, the serum was diluted with negative control serum (to maintain the immunoglobulin concentration) so that at least two dilutions were in the range of 30% of the precipitated complex. The titration data were plotted and fitted with a hyperbolic curve, and the resulting titer was calculated from the initial asymptote.
lod, precision, and diagnostic accuracy of eu 3ϩ assay
We made an effort to adhere to the published guidelines for diagnostic accuracy for our test (19 ) . The calculated LOD, determined as 3 SD of the blank with 10 L of serum and Eu 3ϩ -␣-CTx-nAChR complex at 70% saturation, was 0.3 nmol/L. None of the negative sera tested gave a value exceeding that limit. The typical "withinrun" CV for triplicates in the isotopic assay was ϳ5%. The imprecision of the fluorescence method was greater, with a within-run CV, for triplicates, of ϳ10% and a betweenrun CV ϳ16%. The usefulness of the fluorescence method, however, was demonstrated by comparison of titers obtained by the two methods (Fig. 5) . We compared 43 myasthenic sera (with titer values between 0.3 and 1290 nmol/L as determined by the isotopic assay); 8 of those sera (not included in Fig. 5) were seronegative by the isotopic assay, with titers indistinguishable from those of healthy controls (titer Յ0.3 nmol/L), and were negative by the Eu 3ϩ assay as well. We included eight sera with titers of 0.4 -1 nmol/L; three of those gave values Յ0.3 nmol/L in the Eu 3ϩ assay. Two of these three were also near the LOD for the isotopic assay: 0.4 nmol/L. The third serum that was negative in the Eu 3ϩ assay gave a titer of 0.7 nmol/L in the isotopic assay. Overall, the linear regression of data yielded the following equation: y ϭ 1.035x Ϫ 0.013 nmol/L (S y͉x ϭ 0.172 nmol/L; r 2 ϭ 0.977).
Discussion
We established a nonradioactive immunoassay for antibodies to AChRs that used Eu 3ϩ -labeled ␣-CTx rather than 125 I-␣-BuTx. The reagent used to label the antigen is more stable than 125 I-␣-BuTx, the concentration of antibodies can be expressed in molar units as in conventional RIAs, and the results show similar detection limits and identical diagnostic specificity. (A), ϳ100 fmol of nAChR (from human muscle) was treated with various concentrations of labeled Eu 3ϩ -␣-CTx, and the resulting complex was precipitated with a high-titer myasthenic serum (f). With fluorescence detection, 1 fmol of Eu 3ϩ gave ϳ2200 fluorescence counts. Data were subjected to linear fit for negative serum (OE; nonspecific binding) and hyperbolic fit for specific binding. Several nonradioactive methods for the detection of anti-nAChR antibodies have been described previously. One approach is based on solid-phase attachment of nAChR and detection of bound anti-nAChR immunoglobulin by labeled anti-immunoglobulin antibody (20 -23 ) ; another is on the substitution of horseradish peroxidase-labeled ␣-BuTx for 125 I-␣-BuTx in the immunoassay (24 ) . None of these methods has been adopted for routine use, probably because they are less sensitive than the 125 I-␣-BuTx radioimmunoprecipitation assay.
We attempted to use Eu 3ϩ -labeled ␣-BuTx, but the derivatives of ␣-BuTx that we obtained lost much of their affinity for nAChRs. Labeling of ␣-CTx produced a useful derivative. Our preparation probably represents a monosubstituted toxin with DTPA conjugated with either lysine or the N-terminal amino acid (proline). It would be possible to isolate individual positional isomers, but our procedure has been worked out for a mixture of several isomers that are isolated together. Binding analysis of the HPLC-purified fraction used for the experiments suggested the presence of two main components with calculated binding affinities of 3.7 ϫ 10 Ϫ9 mol/L and 145 ϫ 10 Ϫ9 mol/L. As was already noted, the results obtained with the Eu 3ϩ assay correlate closely to the results obtained with the isotopic assay. This was to be expected because the design of both methods is almost identical and the only important difference is in the label used for the ␣-toxin. The described fluorescence assay can measure concentrations of anti-nAChR antibodies Ͼ0.3 nmol/L, but reliable estimates can be expected for titers Ͼ0.5 nmol/L. This LOD is slightly higher than that of the isotopic assay, which has a LOD in the range of 0.1-0.2 nmol/L. In MG, titers Ͼ0.5 nmol/L are considered positive, whereas titers of 0.2-0.5 nmol/L are evaluated as equivocal [e.g., see ]. Although the isotopic assay might be more advantageous for such "equivocal" cases, the advantages of the nonradioactive fluorescence assay that we describe may make it a useful tool in the diagnosis and follow-up of myasthenic patients. 
